跳至主要内容
临床试验/NCT00404339
NCT00404339已完成1 期

Adjuvant p53 Peptide Loaded DC-Based Therapy for Subjects With Squamous Cell Cancer of the Head and Neck (A Phase I Safety and Immunogenicity Trial)

Robert Ferris2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2005年9月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
17
试验地点
2
主要终点
Biologic response rate

研究概览

简要总结

RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells.

PURPOSE: This randomized phase I trial is studying the side effects of vaccine therapy in treating patients with head and neck cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the toxicity of intranodally injected autologous dendritic cells (DC) loaded with wild-type p53 peptides with or without T-helper peptide epitope in patients with squamous cell carcinoma of the head and neck.

Secondary

  • Determine the local and systemic immunomodulatory effects of this vaccine in these patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Biologic response rate

Immunologic response rate as measured by ELISPOT assay prevaccination and at days 14 and 18

Toxicity profile and overall toxicity rates

次要结局

未报告次要终点

研究者

发起方
Robert Ferris
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Robert Ferris

UPMC Endowed Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngology

University of Pittsburgh

研究点 (2)

Loading locations...

相似试验

Vaccine Therapy in Treating Patients With Head and... | 临床试验